This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
billion loan to help finance any moves it might wish to make next year relating to German TV business ProSiebenSat.1, Restrictions on pharmaceutical ads look likely, says Madison and Wall’s CEO, CFA and principal Brian Wieser. And this would hit TV particularly hard, since pharmaceutical companies invest heavily in TV.
For brands going down this route, the classic approach involves forming an internal agency-style trading desk and equipping them with a demandsideplatform (DSP). Going all-in can be a monumental task, but with the right preparation, the right planning, and the right implementation, the returns are potentially mouth-watering.
An Example of the All-In Set Up For brands going down this route, the classic approach involves forming an internal agency-style trading desk and equipping them with a demandsideplatform (DSP). Bite off only what you can chew.
Measurement Firm Happydemics Raises 13 Million in Series B Funding Happydemics, a Paris-based ad tech firm, announced it has raised 13 million in a Series B funding round, led by Wille Finance and Adelie Capital. “Our Brand lift technology delivers exactly that. .
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content